Participants will learn good practices in combining data from both in vitro and clinical studies, whilst gaining experience in using such data within physiologically-based dynamic models to evaluate the DDI liability of drug candidates.

• Static vs. dynamic models (including discussion around regulatory guidance)

• Metabolic and transporter mediated DDIs

• Competitive inhibition, mechanism-based inhibition, induction, and suppression

• Complex DDIs involving combined interaction mechanisms and multiple inhibitors (including inhibitory metabolites)

• Importance of in vitro study design

• The role of non-hepatic metabolism in DDIs

• Use of parameter estimation and sensitivity analysis

• Optimal clinical study design

• Special populations—identification of individuals at risk of DDI